Trials / Completed
CompletedNCT04972617
Characterization of the Efficacy of Furosemide Depending on Albumin Function
Characterization of the Efficacy of Furosemide Depending on Albumin Function - a Prospective Monocentric Observational Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 50 (actual)
- Sponsor
- University of Rostock · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
During this prospective, uncontrolled and non-interventional observational study, the influence of albumin function on the efficacy of furosemide will be investigated. The aim of the study is to provide information on the efficacy of furosemide depending on albumin function.
Detailed description
In patients with intravenous furosemide administration, an additional 15 ml of blood is taken for the analysis of specific parameters as part of the blood sampling necessary for the treatment of the patient. The effect of furosemide is assessed on the basis of the patient's urine excretion. For this purpose, fluid intake and excretion are balanced over 6 hours. The blood sample is taken at the beginning of the balancing period. In addition, the albumin concentration, ABiC, as well as the total and free concentration of furosemide in the collected urine are determined.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIAGNOSTIC_TEST | albumin function analysis (ABIC) | After centrifugation (10 minutes at 4000 rpm), the plasma is aliquoted and stored at minus 80° C until further analysis. The free as well as the total furosemide concentration is determined by HPLC. In addition to the characterisation of the albumin function by means of the ABiC, these samples can also be used for the determination of the albumin concentration (prerequisite for the determination of the ABiC) and free furosemide concentration as well as for the determination of further parameters relevant for the albumin function. |
Timeline
- Start date
- 2022-05-17
- Primary completion
- 2022-10-31
- Completion
- 2022-10-31
- First posted
- 2021-07-22
- Last updated
- 2022-11-03
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT04972617. Inclusion in this directory is not an endorsement.